[go: up one dir, main page]

MX2019013260A - Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas. - Google Patents

Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas.

Info

Publication number
MX2019013260A
MX2019013260A MX2019013260A MX2019013260A MX2019013260A MX 2019013260 A MX2019013260 A MX 2019013260A MX 2019013260 A MX2019013260 A MX 2019013260A MX 2019013260 A MX2019013260 A MX 2019013260A MX 2019013260 A MX2019013260 A MX 2019013260A
Authority
MX
Mexico
Prior art keywords
oxi
sulfonil
dimethylprop
noate
octan
Prior art date
Application number
MX2019013260A
Other languages
English (en)
Other versions
MX385265B (es
Inventor
Eric M Gordon
John Freund
Mark A Gallop
Matthew Alexander James Duncton
Original Assignee
Arixa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arixa Pharmaceuticals Inc filed Critical Arixa Pharmaceuticals Inc
Publication of MX2019013260A publication Critical patent/MX2019013260A/es
Publication of MX385265B publication Critical patent/MX385265B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Storage Device Security (AREA)

Abstract

Se describen compuestos que inhiben la ß-lactamasa, métodos terapéuticos de uso de los compuestos que inhiben la ß-lactamasa, particularmente en combinación con antibiótico de ß-lactama y composicoines farmacéuticas de los mismos. Los compuestos que inhiben la ß-lactamasa son apropiados para administración oral.
MX2019013260A 2017-05-10 2018-05-02 Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas MX385265B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762504523P 2017-05-10 2017-05-10
US201762551043P 2017-08-28 2017-08-28
US15/934,497 US10085999B1 (en) 2017-05-10 2018-03-23 Beta-lactamase inhibitors and uses thereof
PCT/US2018/030652 WO2018208557A1 (en) 2017-05-10 2018-05-02 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections

Publications (2)

Publication Number Publication Date
MX2019013260A true MX2019013260A (es) 2021-08-11
MX385265B MX385265B (es) 2025-03-18

Family

ID=63639355

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013260A MX385265B (es) 2017-05-10 2018-05-02 Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas
MX2021008379A MX2021008379A (es) 2017-05-10 2019-11-06 Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008379A MX2021008379A (es) 2017-05-10 2019-11-06 Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas.

Country Status (22)

Country Link
US (6) US10085999B1 (es)
EP (1) EP3625233B9 (es)
JP (2) JP6909924B2 (es)
KR (1) KR102411517B1 (es)
CN (1) CN110662746B (es)
AU (2) AU2018266566B2 (es)
CA (2) CA3153583A1 (es)
DK (1) DK3625233T5 (es)
ES (1) ES2955871T3 (es)
FI (1) FI3625233T5 (es)
HR (1) HRP20230977T1 (es)
HU (1) HUE062752T2 (es)
IL (2) IL296379B2 (es)
LT (1) LT3625233T (es)
MX (2) MX385265B (es)
PL (1) PL3625233T3 (es)
PT (1) PT3625233T (es)
RS (1) RS64547B9 (es)
RU (1) RU2753401C2 (es)
SG (2) SG11201909429VA (es)
SI (1) SI3625233T1 (es)
WO (1) WO2018208557A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3478693T3 (pl) 2016-06-30 2021-12-13 Qpex Biopharma, Inc. Pochodne kwasu boronowego i ich zastosowania terapeutyczne
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
KR102455390B1 (ko) * 2017-10-02 2022-10-17 아릭사 파마슈티컬스 인코포레이티드 아즈트레오남 유도체 및 이의 용도
AU2019256351B2 (en) 2018-04-20 2024-02-29 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
JP7437847B2 (ja) 2018-10-01 2024-02-26 アリクサ ファーマシューティカルズ、インコーポレイテッド レレバクタムの誘導体およびその使用
CN113614084A (zh) * 2019-03-12 2021-11-05 阿里萨制药公司 阿维巴坦衍生物的晶型
US12162883B2 (en) 2019-04-26 2024-12-10 Merck Sharp & Dohme Llc Process for the preparation of intermediates useful for making (2S,5R)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
JP7673052B2 (ja) * 2019-08-29 2025-05-08 アリクサ ファーマシューティカルズ、インコーポレイテッド 細菌感染症を処置するためのベータラクタム抗生物質およびアビバクタム誘導体の経口投与される組合せ
US20210186983A1 (en) * 2019-12-20 2021-06-24 Arixa Pharmaceuticals, Inc. Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
CN117157078A (zh) * 2021-04-05 2023-12-01 Qpex生物制药有限公司 头孢布烯给药方案
CN115448920B (zh) * 2022-10-14 2025-01-03 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
CN119431373B (zh) * 2024-07-24 2025-08-08 科睿迪(南京)医药科技有限公司 一种β-内酰胺酶抑制剂及其用途
CN119841826A (zh) * 2024-09-30 2025-04-18 科睿迪(南京)医药科技有限公司 二氮杂二环类β-内酰胺酶抑制剂及其应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3658849A (en) 1969-02-19 1972-04-25 Reynolds Tobacco Co R Treatment of 2-substituted aldehydes with lead dioxide
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3045373A1 (de) 1980-12-02 1982-07-01 Henkel KGaA, 4000 Düsseldorf Verwendung von estern der 3-hydrody-2,2-dimethylpropionsaeure als riechstoffe, diese enthaltende riechstoffkompositionen und 3-hydroxy-2,2-dimethyl-propionsaeurepropylester
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
CA2266629C (en) 1996-10-01 2002-04-16 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
EP1048301A4 (en) 1998-01-16 2005-03-09 Takeda Chemical Industries Ltd COMPOSITIONS WITH DELAYED ACTIVE INGREDIENTS, PROCESS FOR THEIR PREPARATION AND THEIR USE
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
WO2002092606A1 (en) 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Fused imidazolidine derivatives, process for preparation of the same and use thereof
AU2004272077A1 (en) 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
WO2009033054A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090082464A1 (en) 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009052191A1 (en) 2007-10-15 2009-04-23 Xenoport, Inc. Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
ES2533826T3 (es) 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
GB0801401D0 (en) 2008-01-25 2008-03-05 Barry Callebaut Ag Composition
WO2009100045A1 (en) 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
EP2334636A2 (en) 2008-09-19 2011-06-22 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
CN102638981B (zh) 2009-10-14 2015-07-22 默沙东公司 提高p53活性的取代的哌啶和其用途
NZ603198A (en) 2010-04-20 2013-10-25 Taisho Pharmaceutical Co Ltd Novel hydroxamic acid derivative
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
DE102010033015B4 (de) 2010-07-31 2016-03-17 Gaplast Gmbh Einmal-Applikator
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
SI2657234T1 (sl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
US9101140B2 (en) 2011-05-30 2015-08-11 Sumitomo Chemical Company, Limited Cyclohexanone compounds and herbicides comprising the same
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
EP2857401B8 (en) * 2012-05-30 2019-11-20 Meiji Seika Pharma Co., Ltd. NOVEL ß-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME
MX2016013431A (es) 2014-04-18 2017-04-13 Wockhardt Ltd Composiciones farmaceuticas que comprenden agentes antibacterianos.
SG11201701956TA (en) 2014-09-12 2017-04-27 Toyama Chemical Co Ltd Novel pharmaceutical composition containing hydroxamic acid derivative or salt thereof
SG11201701955UA (en) 2014-09-12 2017-04-27 Toyama Chemical Co Ltd Method for using novel hydroxamic acid derivative and antibacterial substance in combination
WO2016116788A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017037607A1 (en) * 2015-09-01 2017-03-09 Wockhardt Limited (aminomethylidene)amino-substituted (2s,5r)-6-(sulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide derivatives with antibacterial activity
US10167283B2 (en) 2015-09-16 2019-01-01 Suanzhu Pharma Co., Ltd. β-lactamase inhibitors and uses thereof
US20170165371A1 (en) 2017-02-22 2017-06-15 Joel Steven Goldberg Novel synthesis of potential ester prodrugs
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof

Also Published As

Publication number Publication date
JP6909924B2 (ja) 2021-07-28
EP3625233B9 (en) 2023-10-25
SI3625233T1 (sl) 2023-10-30
FI3625233T5 (fi) 2023-12-12
IL296379A (en) 2022-11-01
IL270330A (es) 2019-12-31
CN110662746A (zh) 2020-01-07
IL296379B2 (en) 2024-10-01
JP2021165298A (ja) 2021-10-14
EP3625233A1 (en) 2020-03-25
JP2020519684A (ja) 2020-07-02
AU2018266566B2 (en) 2020-06-04
LT3625233T (lt) 2023-08-25
CA3153583A1 (en) 2018-11-15
US20200046724A1 (en) 2020-02-13
RU2019135891A3 (es) 2021-06-10
RU2753401C2 (ru) 2021-08-16
CN110662746B (zh) 2022-08-19
AU2020227077B2 (en) 2022-10-20
DK3625233T3 (da) 2023-08-28
RU2021121906A3 (es) 2022-02-17
EP3625233B1 (en) 2023-07-12
RU2021121906A (ru) 2021-08-02
IL296379B1 (en) 2024-06-01
US20240415847A1 (en) 2024-12-19
WO2018208557A1 (en) 2018-11-15
SG11201909429VA (en) 2019-11-28
ES2955871T3 (es) 2023-12-07
HUE062752T2 (hu) 2023-12-28
FI3625233T3 (fi) 2023-09-05
NZ758353A (en) 2021-10-29
US20230201218A1 (en) 2023-06-29
PL3625233T3 (pl) 2023-10-23
CA3062619A1 (en) 2018-11-15
RU2019135891A (ru) 2021-06-10
CA3062619C (en) 2022-06-21
US20200297733A1 (en) 2020-09-24
US10500211B2 (en) 2019-12-10
KR20200004874A (ko) 2020-01-14
HRP20230977T1 (hr) 2023-12-08
RS64547B1 (sr) 2023-09-29
MX2021008379A (es) 2021-08-11
PT3625233T (pt) 2023-09-19
KR102411517B1 (ko) 2022-06-21
IL270330B (en) 2022-10-01
SG10202102306TA (en) 2021-04-29
AU2018266566A1 (en) 2019-11-07
BR112019023598A2 (pt) 2020-05-26
IL270330B2 (en) 2023-02-01
US10722521B2 (en) 2020-07-28
MX385265B (es) 2025-03-18
US20190022102A1 (en) 2019-01-24
ES2955871T9 (es) 2023-12-19
DK3625233T5 (da) 2024-02-05
US10085999B1 (en) 2018-10-02
AU2020227077A1 (en) 2020-09-24
RS64547B9 (sr) 2024-02-29

Similar Documents

Publication Publication Date Title
MX2019013260A (es) Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas.
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
BR112022008375A2 (pt) Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste
CO2022008969A2 (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO2020015437A2 (es) Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores pd-l1
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
MX373935B (es) Compuestos antiproliferativos y métodos de uso de los mismos.
ECSP19051352A (es) Inhibidores selectivos de jak1
BR112017007662A2 (pt) composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY34723A (es) ?compuestos de 7-oxo-1,6-diazabiciclo[3.2.1]oct-3-en-6-ilo sustituidos para usarse como inhibidores de la betalactamasa?.
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
GEAP202014683A (en) 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors
MX376113B (es) Derivados de azabenzimidazoles como moduladores del receptor ampa, y el uso de los mismos en el tratamiento de enfermedades asociadas con los receptores ampa.
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
BR112018007811A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
CO6382176A2 (es) Derivados de urea heterociclicos y metodos de uso de los mismos-332
UY31865A (es) Derivados de urea heterocíclicos y métodos para la utilización de los mismos
ECSP23080267A (es) Compuestos de lactivicina, su preparación y uso como agentes antibacterianos
ZA202203107B (en) Azaindole carboxamide compounds for the treatment of mycobacterial infections
SA518400554B1 (ar) صيغة صيدلانية تشتمل سينيول وأموكسيسيللين
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
CL2015001603A1 (es) Nuevos compuestos biciclicos y su uso como agentes antibacterianos e inhibidores de ß-lactamasa.